HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on AEON Biopharma but has significantly lowered the price target from $18 to $6.
May 15, 2024 | 6:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on AEON Biopharma but has significantly lowered the price target from $18 to $6.
The significant reduction in the price target from $18 to $6 suggests a more cautious outlook on AEON Biopharma's future performance, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100